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Abstract
Background: Lung cancer is the leading cause of cancer-related deaths worldwide. Early detection is considered
critical for lung cancer treatment. MicroRNAs (miRNAs) have shown promise as diagnostic and prognostic
indicators. This study was to identify specific miRNAs with diagnostic and prognostic value for patients with lung
cancer, and to explore the correlation between expression profiles of miRNAs and patient survival.
Methods: Gene expression of members of the miR-183 family (miR-96, miR-182, and miR-183) were examined in
70 paired samples from lung cancer patients (primary cancer and non-cancerous tissues and sera), as well as 44
serum samples from normal volunteers and lung cancer cell lines by quantitative real-time reverse transcription
polymerase chain reaction (RT-qPCR). The correlation between the expression of miRNAs in tissues, sera, and
patient overall survival were also examined by log-rank and Cox regression analysis.
Results: Expression levels of members of the miR-183 family in lung cancer tumor and sera were higher than that
of their normal counterparts. The miR-96 expression in tumors was positively associated with its expression in sera.
Log-rank and Cox regression analyses demonstrated that high expression of tumor and serum miRNAs of the miR-
183 family were associated with overall poor survival in patients with lung cancer.
Conclusions: Our results suggest that the expressions of miR-96, miR-182, and miR-183 in tumor and sera may be
considered potential novel biomarkers for the diagnosis and prognosis of lung cancer.
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Background
Lung cancer is the leading cause of cancer-related
deaths worldwide [1], and the current pathologic staging
is inadequate to predict outcome for patient treatment.
The development of molecular target therapy has
improved the management of patients with lung cancer
who are at high risk of relapse following surgery. One of
the most promising classes of molecular markers in
tumor prognosis is the small noncoding RNAs, or
microRNAs (miRNAs) [2-4]. MiRNAs, acting as onco-
genes or tumor suppressors, have been shown to regu-
late the expression of hundreds of targeted genes at the
posttranscriptional level and are implicated in the
pathogenesis and therefore prognosis of human cancers
[5-9]. For non-small cell lung cancer (NSCLC) in parti-
cular, previous reports have indicated that miRNA
expression patterns could be potential biomarkers used
for diagnosis, prognosis, and personalized therapy
[4,8-11]. In addition, some studies found that human
serum or plasma contained large numbers of stable
miRNAs and that the expression profiles of some speci-
fic circulating miRNAs could be useful in the diagnosis
and prognosis of cancer [12-14].
In our study, we performed a miRNA expression array
by quantitative real-time reverse transcription polymer-
ase chain reaction (RT-qPCR) and identified the expres-
sion of members of the miR-183 family (miR-96, miR-
182, and miR-183) when comparing primary NSCLC
tumor with adjacent normal lung tissues. The miR-183
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bers of this family have been identified as potential
oncogenes in several tumor types, including medullo-
blastomas [15], breast cancer [16], prostate cancer [17],
hepatocellular tumors [18], and colon cancer [19,20], as
well as lung cancer [21,22]. However, the role that these
miRNAs play in the diagnosis and prognosis of lung
cancer patients remains unknown.
We compared the expression levels of the miR-183
family in lung cancer cell lines with normal lung cells,
and in primary tumor tissues and sera from NSCLC
patients with normal volunteers. Our results indicate for
the first time that members of the miR-183 family
expressed in tumors and sera may be potential biomar-
kers in the diagnosis and prognosis of human lung
cancer.
Methods
Sample population
NSCLC and matched adjacent noncancerous tissues
were collected from patients undergoing lung resection
surgery from January 2008 to May 2008 at Zhoushan
Hospital, Zhejiang Province, China. The details of
patients were shown in Table 1. Eligible samples were
obtained from primary lung cancer that had not
received any preoperative radiotherapy or chemotherapy,
and in which there was no co-existing disease. More-
over, we excluded tissue blocks of mixed histology, or
specimens with insufficient tumor material. The sub-
types included 36 squamous-cell carcinoma and 34 ade-
nocarcinoma. All human materials were obtained with
patients’ informed consent and the Ethical Review Com-
mittee of Zhoushan Municipal Government of China
approved this study.
Upon removal, the surgical specimens were immedi-
ately transported to the clinical pathology laboratory,
where each sample was placed in a cryovial and flash-
frozen in liquid nitrogen within 30 minutes and then
stored at -80°C until analyzed. Sera from all NSCLC
patients and healthy volunteers were also collected.
There was no significant difference in gender or age
between NSCLC patients and healthy volunteers. All
cases were reviewed by two pathologists and diagnoses
were confirmed according to the criteria recently estab-
lished by the National Comprehensive Cancer Network
(NCCN).
Cell lines and cell culture conditions
The following cell lines were cultured individually in
RPMI-1640 medium (Gibco): A549, H1299, and SPC-A1
human lung adenocarcinoma; 95C and 95D human
giant-cell lung carcinoma; NCI-H466 human small cell
lung carcinoma; NCI-H460 human large-cell lung carci-
noma; and human bronchial epithelia. In addition, SK-
MES1 human squamous-cell lung carcinoma cells were
cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM; Gibco). Both media were supplemented with
10% fetal bovine serum (Gibco), 2 mM L-glutamine, 100
IU/mL penicillin, and 100 mg/mL streptomycin. Cells
were incubated in 5% CO2 at 37°C.
RNA isolation
Total RNA isolated from 6 NSCLC and 6 matched adja-
cent noncancerous tissues by the Trizol (Invitrogen)
method were prepared for miRNA microarray according
to the manufacturer’s instructions. miRNA isolated from
cells, tissues, and sera were obtained using the miRNA
Isolation Kit and mirVana PARIS Kit (Applied Biosys-
tems, Foster City, CA, USA), according to the manufac-
turer’s protocol. The specific sources of miRNAs were:
10
6 to 10
7 cells (described above), 100 mg of tissue from
each of 70 NSCLC patients and matched adjacent non-
cancerous tissues, and circulating miRNAs from 600 μL
of serum from each of 70 NSCLC patients and 44 nor-
mal volunteers. The RNA concentration was measured
by a NanoDrop ND-1000 spectrophotometer (nm
Table 1 Clinico-pathological Characteristics of 70 Patients
with NSCLC
Characteristics n
Mean age
<6 0 3 4
≥60 36
Sex
Male 56
Female 14
Smoking
Nonsmokers 24
Current smokers 46
Tumor size
0-3 cm 18
> 3 cm 52
Histological classification
Adenocarcinoma 34
SCC 36
Invasion to lung membrane
Yes 17
No 53
differentiation
Mod-well 46
Poor 24
Lymph node
Negative 38
Positive 32
Stage classification
StageI 36
StageII,III and IV 34
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Technologies).
MicroRNA microarray and data analysis
Three to five micrograms of total RNA were labeled by
ligating the fluorescent RNA-linker 5’-cytidine bispho-
sphate-cyanine 3 (pCp-Cy3) to the 3’ end of miRNAs.
Slides were then incubated with the labeled RNA and
washed. Five hundred and nine miRNAs passed the
initial screening criteria of the normalized median fluor-
e s c e n c es i g n a l .T h ei m a g e sw e r ea n a l y z e du s i n gS p o t -
Reader software (Niles Scientific, Portola Valley, CA).
The significance of differences in expression levels was
assessed by a two-sided paired t-test within the signifi-
cance analysis of microarrays (SAM). P < 0.05 indicated
a significant difference.
RT-qPCR of miRNA derived from lung cancer cell lines
and lung primary tissues
The amounts of the miRNAs in lung tumors, analyzed
by microarray, were quantified by RT-qPCR using Taq-
Man MicroRNA Assay Kits (Applied Biosystems, USA).
Briefly, the reverse transcription (RT) reaction was car-
ried out with a TaqMan MicroRNA Reverse Transcrip-
tion Kit (Applied Biosystems) according to the
instruction of the protocol. One to ten nanograms of
total RNA per 15 μL RT reaction were processed at 16°
C for 30 min, 42°C for 30 min, and 85°C for 5 min. Fol-
lowing the RT, quantitative real-time PCR was per-
formed in an ABI 7500 Real-Time PCR system (Applied
Biosystems) at 95°C for 10 min, followed by 40 cycles of
95°C for 15 s and 60°C for one minute.
The cycle threshold (Ct) values were calculated with
SDS 2.0.1 software (Applied Biosystems). The average
expression levels of miRNAs in tissues and sera were
normalized with U6 small nuclear RNA (snRNA) and
U48 snRNA using the 2
-ΔΔCt method [23]. The mean Ct
value in three candidate miRNAs was calculated, exclud-
ing outliers (i.e., replicates with a Ct differing by > one
cycle from the median). If CtU6, ave and CtU48, ave were
not within 20 and 32 cycles, the assay was repeated.
Samples with low U6 or U48 snRNA levels were not
included in this study.
Statistical analyses
The statistical analyses were performed with Graphpad
Prism 5.0 statistical software. The data were examined
according to the degree of homogeneity. The paired t-
test, unpaired t-test, or Mann-Whitney U-test was used
to analyze the correlation between the miRNA expres-
sion levels and clinical-pathological features of the
patients. The paired sample t-test was used to compare
the differences in miRNA expression between lung tis-
sues and sera. All data were expressed as the mean ±
standard error of the mean (SEM). Binary logistic
regression was used to assess associations between the
miR-183 family and the clinical-pathological features of
the patients. Survival analysis was performed with the
Kaplan-Meier method, and the log-rank test was used to
compare survival times between groups and was
adjusted according to age and tumor stages. The Cox
hazard regression model was used to analyze the miR-
NAs as risk factors for lung cancer. A probability (P)-
value < 0.05 was considered statistically significant.
Results
Expression of the miR-183 family of miRNAs in lung
tissues, sera, and cell lines
MicroRNA arrays were performed from 6 lung cancer
and 6 matched adjacent normal lung tissues that con-
tained 723 human miRNA probes (from version 10.0 of
miRBase sequence database, http://www.mirbase.org/). A
total of 94 miRNAs were differentially expressed
between lung carcinoma and the normal counterpart.
Among those, we selected for further study 3 cluster
miRNAs, namely miR-96, miR-182, and miR-183, based
on the magnitude of fold changes (10.77-, 10.75-, and
6.62-fold, respectively) and probability values (P =
0.00127, 0.00209 and 0.00190), as shown in our previous
study [24].
We validated the three miRNAs in 70 pairs of lung
carcinoma and the corresponding noncancerous lung
tissues by RT-qPCR. We showed that, compared with
the adjacent normal lung tissues, the levels of the
mature forms of miR-96, miR-182, and miR-183 were
significantly increased in lung cancer tissues (P< 0.0001
for each; Figure 1A). The highly expressed (> 2-fold
changes) miR-96, miR-182 and miR-183 were observed
in 42 (60.0%), 54 (77.1%) and 48 (68.6%) of the 70 sam-
ples, respectively.
Compared to the sera of normal volunteers, the
expression levels of miR-96, miR-182, and miR-183 in
the sera of NSCLC patients were significantly higher in
62 (88.6%), 38 (54.3%), and 32 (45.7%) of the 70 samples
(P< 0.0001, = 0.0130, and = 0.0086, respectively; Figure
1B). A correlation was also found between the serum
and tumor levels of miR-96 (Pearson r = 0.419, P=
0.0003), but not for miR-182 (Pearson r = 0.0464, P=
0.703) or miR-183 (Pearson r = 0.118, P=0.332). This
suggested that serum levels of miR-96, but not miR-182
and miR-183, might correspond to the levels of tumor
miR-96 (Figure 2).
Finally, we tested levels of miRNAs in different types
of lung cancer vs. normal cell lines. The results from
RT-qPCR were expressed as fold changes in each
miRNA in lung cancer cells relative to normal cells. As
shown in Figure 3, the expression levels of miR-96 were
higher in 8 lung cancer cell lines. High levels of miR-
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of miR-183 in H466 and SK-MES1. The highest expres-
sion levels for the three miRNAs were found in NCI-
H466 cells. In addition, the expression levels of all three
were higher in A549 and 95D cells than in H1299 and
95C cells.
Correlation between miR-183 family and clinical-
pathological features of NSCLC
We also analyzed with the Mann-Whitney U-test the
correlation between miRNAs and clinical-pathological
features of NSCLC (including age, gender, smoking his-
tory, histological classification, lymph node metastasis,
differentiation, and clinical-pathological stage) to under-
stand better the potential role of these miRNAs in
NSCLC development and progression. Our results
showed that overexpression of miR-183 in tumors was
strongly associated with lymph node metastasis, invasion
of the lung membrane, and advanced clinical stage of
NSCLC (P=0.0086, 0.0222 and 0.0478, respectively).
Overexpression of miR-182 in tumors was positively
related to invasion of the lung membrane and tumor size
>3c m( P = 0.0140 and 0.0464, respectively). In sera,
miR-182 overexpression was also positively related to
invasion of the lung membrane and tumor size > 3 cm (P
= 0.0222 and 0.0351, respectively). Compared to lung
adenocarcinoma, higher expression of miR-96, miR-182,
and miR-183 in tumors, and miR-96 in sera, were found
in squamous cell lung carcinoma (P=0.0216, 0.0190,
0.0042, and 0.0310, respectively; Figure 4).
We also analyzed the association between levels of the
miR-183 family and clinical-pathological features with a
Figure 1 RT-qPCR analysis of miRNAs in lung carcinoma and matched noncancerous tissues. (A) Paired sample t-test was used to
compare the differential expressions of miR-96, miR-182, and miR-183 in 70 lung carcinoma and matched noncancerous tissues. The P-values for
miR-96, miR-182, and miR-183 were P< 0.0001 for each. (B) Unpaired sample t-test was used to compare the differential expressions of miR-96,
miR-182, and miR-183 in sera from 70 lung cancer patients and 44 healthy controls. The P-values for miR-96, miR-182, and miR-183 were P
<0.0001, = 0.0130, and = 0.0086, respectively. *Indicates a significant difference between groups (P < 0.05).
Figure 2 Correlation between the expressions of miR-96, miR-182, and miR-183 in tissues vs. sera from lung cancer patients. Pearson’s
correlation between the expression of miR-96, miR-182, and miR-183 in NSCLC tissues and sera are shown. The correlation rate of miR-96 was
0.419, P=0.0003; miR-182 was 0.0464, P=0.703; and miR-183 was 0.118, P=0.332.
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Page 4 of 10Figure 3 RT-qPCR analysis of lung cancer cell lines. Total RNA was isolated from several different lung cancer cells lines by the Trizol method
(Invitrogen) according to the manufacturer’s instructions, and qRT-PCR was performed using TaqMan MicroRNA Assay Kits (Applied Biosystems).
The average expression levels of miR-96, miR-182, and miR-183 in tissues and sera were normalized using the 2-
ΔΔCt method relative to the
average of U6 snRNA and U48 snRNA. The average Ct value of triplicates in three candidate miRNAs was calculated. *Indicates a significant
difference compared to HBE cells (P < 0.05).
Figure 4 Correlation of expression of miR-183 family with clinical-pathological features of lung cancer. The Mann-Whitney U-test was
used to examine the correlation between miR-183 family levels and clinical-pathological features. The results showed that (A) Tumor miR-96,
miR-182, and miR-183, and serum miR-96 expression were higher in squamous-cell lung carcinoma than in adenocarcinoma (P=0.0216, 0.0190,
0.0042, and 0.0310, respectively). (B) Tumor miR-183 expression was higher in NSCLC patients with lymph node metastasis than without lymph
node metastasis (P=0.0086). (C) Tumor miR-182 and miR-183 expressions were higher in NSCLC patients with tumor invasion to lung
membrane than without invasion to lung membrane (P=0.0222 and 0.0140, respectively). (D) Tumor and serum miR-182 levels were higher in
NSCLC patients with tumor size > 3 cm than those with tumor size < 3 cm (P=0.0464 and 0.0351, respectively). (E) Tumor miR-183 expression
was higher in stages II, III, and IV NSCLC samples than in stage I. Differences were significant after the Mann Whitney U-test. *Indicates a
significant difference between groups (P < 0.05).
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patients over 60 years old, or with squamous-cell lung
carcinoma, had higher levels of tumor miR-96. Patients
with squamous-cell lung carcinoma or tumor invasive to
lung membrane had higher levels of tumor miR-183.
Patients with poor differentiation had higher levels of
miR-96, miR-182 and miR-183 in sera (Table 2).
Correlation between expression of miRNAs of the miR-
183 family and overall survival of NSCLC patients
Next, we investigated whether the expressions of miR-
96, miR-182, and miR-183 were correlated with overall
survival of NSCLC patients. Specifically, we used the
Kaplan-Meier method, log-rank test and univariate Cox
hazard regression model to analyze the correlation
between overall survival of NSCLC patients and the
expressions of miR-96, miR-182, and miR-183 in tumors
(medians of 2
-ΔΔCt values: 6.45, 6.25, and 4.44, respec-
tively) and in sera (medians 5.98, 2.08, and 1.84). The
results showed that high expressions of miR-96, miR-
1 8 2a n dm i R - 1 8 3i nt u m o r sa n ds e r aw e r ei n d e p e n -
dently correlated with shorter overall survival of NSCLC
patients (log-rank test: P=0.0039, 0.0027, 0.0053,
respectively in tumors, and P=0.0017, 0.0025, and
0.0046 in sera; Figure 5).
We also examined if the expressions of miR-96, miR-
182, and miR-183 in tumors and sera were correlated
with clinical-pathological features of the patients, with
hazard ratios (adjusted for sex, age and tumor stage) of
9.637, 7.163, 8.616, P = 0.005, 0.010, and 0.005 respec-
tively in tumors and with hazard ratios (adjusted for sex,
age and tumor stage) of 5.512, 5.327, 5.972 yielded P =
0.027, 0.030, and 0.022 respectively (Table 3) in sera.
This result suggested that miR-96, miR-182 and miR-
183 in tumor and sera independently contributed to the
overall survival of lung cancer patients
Discussion
Lung carcinoma is one of the most common malignan-
cies in the world, and is the leading cause of cancer
death in men and women in the United States with a
dismal five-year survival rate (< 15%) [1]. Although
recent advances have been made in improving diagnosis
and treatment strategies, the prognosis of lung cancer
patients remains unchanged and early detection is criti-
cal in improving survival duration. Studies have shown
that miRNAs play an important role in tumorigenesis
and they have been considered potential biomarkers for
early diagnosis and prognosis in a wide variety of
human cancers [6,14,25,26]. More importantly, circulat-
ing miRNAs might act as noninvasive blood-based bio-
markers for cancer diagnosis [14,27]. One recent report
demonstrated that miRNAs in tissues and plasma could
have a critical role as molecular predictors of lung can-
cer development and management outcome [28].
The upregulation of members of the miR-183 family
(miR-96, miR-182, miR-183) has been reported in sev-
eral types of cancers [15-20]. Consistent with our
results, members of the miR-183 family were elevated in
lung cancer, revealed by novel rank-based statistical
methods using microarrays [21,22,29]. miR-96, a known
onco-miRNA, targets the tumor suppressor gene fork-
head box O3 (FOXO3; a transcription factor that plays
important roles in tumorigenesis) by binding to the 3
’-
UTR of FOXO3 mRNA and thereby mediating protec-
tion against apoptosis and promoting cell survival
[16,30]. Studies have also reported that miR-27a, miR-
96, miR-182, and miR-183 coordinately regulated the
Table 2 Binary logistic regression analysis for an association between the expression levels of the miR-183 family and
clinical-pathological features of patients
subset Exp (B)
(95% confidence interval)
P-value
Tumor miR-96 High, > 6.45/low, < 6.45
Age < 60/≥60 2.857 (1.080-7.559) 0.034*
Histological classification adenocarcinoma/SCC 3.667 (1.366-9.842) 0.010*
Tumor miR-183 High, > 4.44/low, < 4.44
Histological classification adenocarcinoma/SCC 3.667 (1.366-9.842) 0.010*
Invasion to lung membrane Negative/positive 3.750 (1.072-13.121) 0.039*
Serum miR-96 High, > 5.98/low, < 5.98
Differentiation poor/Mod-well 0.321 (0.114-0.905) 0.032*
Serum miR-182 High, > 2.08/low, < 2.08
Differentiation poor/Mod-well 0.178 (0.059-0.537) 0.002*
Serum miR-183 High, > 1.84/low, < 1.84
Differentiation poor/Mod-well 0.321 (0.114-0.905) 0.032*
Binary logistic regression analysis. *Indicates a significant difference (P< 0.05).
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geting the mRNA FOXO1 3’-UTR [31,32]. In addition,
miR-183 functioned as an onco-miRNA, shown to target
the tumor suppressor transcription factor early growth
response 1 (EGR1), and phosphatase and tensin homo-
log (PTEN) to promote tumor cell migration [19].
Consistent with other reports [6,19,32], we showed
that compared to adjacent non-cancerous lung tissues
Figure 5 Kaplan-Meier survival curves for NSCLC patients plotted for tumor and serum miR-96, miR-182, and miR-183.K a p l a n - M e i e r
survival curves for NSCLC patients based on the median level of fold change. The P-value was calculated using the log-rank test between
patients with high- and low-fold changes. Overall survival of patients with high vs. low miR-183 family expression levels are shown. P < 0.05
indicates a significant difference between groups.
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were highly expressed in lung cancer primary tissues
and sera. Moreover, we found that the expression levels
of miR-96, miR-182, and miR-183 were higher in A549
and 95D cells than in H1299 and 95C cells, respectively.
This implies that the miR-183 family might participate
in tumor metastasis [19,30,33,34]. Consistent with this,
other studies demonstrated that overexpressed miR-96
and miR-182 in melanoma cell lines and breast cancer
cell lines resulted in enhanced oncogenic properties as
well as invasion and metastasis in vitro [30,33]. Sarver et
al. [19] showed that a reduction in miR-183 led to a
decrease in migration in colon cancer and synovial sar-
coma cell lines. Abraham et al. [34] reported that over-
expression of miR-183 in medullary thyroid cancer
predicted lymph node metastasis.
We note that opposite results have also been reported.
According to one study, expression of miR-96 decreased
cell invasion and migration in pancreatic cancer [35].
Another report demonstrated that miR-182 suppressed
cell proliferation of lung cancer cell line A549 in vitro
and tumor growth in vivo through its interference with
the target gene cortactin (CTTN) by epigenetic modifi-
cation [36]. Others found that overexpression of miR-
183 inhibited migration and invasion of lung cancer and
breast cancer cells, by targeting the protein ezrin
[22,37]. These discrepancies might be due to different
cancer cell lines used, and suggest that miRNA might
have distinct functions depending upon cell type [38].
Our results demonstrate an association between the
expressions of miR-183 and miR-182 and metastasis,
invasion, advanced clinical stage, and tumor sizes of
NSCLC. Together with other reports, they imply that
miR-182 and miR-183 might play a role in lung cancer
invasion and metastasis, and progression of NSCLC
[28,30]. Moreover, in our study patients with high tumor
or serum levels of miR-96, miR-182, and miR-183 had
shorter overall post-operative survival times. The hazard
ratios adjusted for gender, age and tumor stage indicated
that these miRNAs could be used independently for eval-
uating the prognoses of NSCLC patients.
In addition, our results demonstrated that serum miR-
NAs might be used as potential biomarkers for diagnosis
and prognosis of lung cancers. Under lung cancer con-
dition, miRNAs entered the circulation mainly from
tumor cells [27]. One study showed that miRNAs in tis-
sue specimens were not detected by Solexa sequencing
in sera [39]. By comparing the expressions of miR-96,
miR-182 and miR-183 in tumors and sera, our results
suggest that the levels of serum and tumor miR-96 were
correlated, while those of miR-182 and miR-183 were
not. These results are consistent with reports from
Mitchell [27] and Hu [39]. The actual role and functions
of these miRNAs need to be further investigated.
Conclusions
Our results show that membe r so ft h em i R - 1 8 3f a m i l y ,
found in tumors and sera, may play a role in the devel-
opment of NSCLC and have potential as biomarkers in
the diagnosis and prognosis of lung cancer. We further
demonstrate a positive correlation between expression
levels of miR-96 in tumors and sera from NSCLC
patients. Further study needs to be done to define the
true value of combined expression profiles of the miR-
1 8 3f a m i l yi nt u m o r sa n ds e r ai nt h ed i a g n o s i sa n d
prognosis of lung cancer.
Table 3 Univariate Cox hazard regression analysis for prognostic factors
subset Adjusted Hazard ratio
(95% confidence interval)
P-value
Gender male/female 0.031 (0.000-5.569) 0.190
Age < 60/≥60 1.630 (0.564-4.716) 0.367
Smoking nonsmoker/current smoker 1.388 (0.306-6.297) 0.671
Tumor size 0-3 cm/> 3 cm 0.766 (0.239-2.455) 0.654
Histological classification adenocarcinoma/SCC 2.739 (0.781-9.604) 0.115
Invasion to lung membrane Negative/positive 1.000 (0.221-4.534) 1.000
Differentiation Mod-well/poor 0.757 (0.182-3.141) 0.701
Lymph node Negative/positive 1.279 (0.425-3.850) 0.661
Stage classification stage I/stage II, III, IV 1.001 (0.334-2.996) 0.999
Tumor miR-96 High, > 6.45/low, < 6.45 9.637 (1.963-47.315) 0.005 *
Tumor miR-182 High, > 6.25/low, < 6.25 7.163 (1.597-32.138) 0.010 *
Tumor miR-183 High, > 4.44/low, < 4.44 8.616 (1.918-38.705) 0.005*
Serum miR-96 High, > 5.98/low, < 5.98 5.512 (1.219-24.915) 0.027 *
Serum miR-182 High, > 2.08/low, < 2.08 5.327 (1.181-24.030) 0.030 *
Serum miR-183 High, > 1.84/low, < 1.84 5.972 (1.289-27.658) 0.022 *
Univariate cox hazard regression analysis. *indicates a significant difference (P< 0.05).
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